INTENSIVE CARE MANAGEMENT IN THE ACUTE PHASE OF PNEUMONIA COMPLICATED BY SEPSIS

Relevance. Pneumonia complicated by sepsis remains one of the leading causes of mortality in intensive care units. Early recognition of life-threatening conditions and the implementation of modern therapeutic strategies are crucial for improving outcomes.
The aim of the research. To summarize current approaches to the diagnosis and intensive care management of community-acquired, hospital-acquired, and viral pneumonia complicated by sepsis, based on recent clinical guidelines.
Materials and Methods. A literature review was conducted covering publications from 2018 to 2024, including national clinical guidelines and international recommendations (IDSA, SSC), as well as clinical studies on novel antibacterial agents, biomarkers, and extracorporeal therapies.
Results. Current treatment strategies include personalized antibiotic therapy, use of prognostic and diagnostic biomarkers (PCT, MR-proADM, suPAR, presepsin), molecular diagnostics (NGS), selective hemoadsorption, and targeted immunotherapy (IL-6 and JAK/STAT inhibitors). Special attention is given to early risk stratification and timely therapeutic intervention.
Discussion. Key issues remain unresalved regarding patient selection for advanced therapies, optimal timing, and criteria for treatment effectiveness. Further research is needed to refine personalized treatment approaches.
Conclusion. Intensive care for pneumonia complicated by sepsis requires an integrated approach based on pathogen profile, disease severity, immune status, and prognostic markers. Incorporation of innovative treatment methods can reduce mortality and improve clinical outcomes.

1. The World Health Organization (WHO). Global Pneumonia Report, 2023. In Russian.

2. Singer M., Deutschman K.S., Seymour K.U., et al. The third international consensus definition of sepsis and septic shock (Sepsis-3). JAMA. 2016; 315 (8): 801–810. doi:10.1001/jama.2016.0287.

3. Rudd K.E., Johnson S.K., Agesa K.M., et al. Global, regional, and national sepsis morbidity and mortality, 1990-2017: an analysis for the Global Burden of Disease Study. Lancet. 2020; 395 (10219): 200–211. doi:10.1016/S0140-6736(19)32989-7.

4. Ministry of Health of the Russian Federation. Clinical recommendations. Community-acquired pneumonia in adults. Approved in 2024 – 73 p. In Russian.

5. Ministry of Health of the Russian Federation. Clinical recommendations. Sepsis (in adults). Approved in 2024 – Moscow: Vidar-M Publishing House, 2025 – 77 p. In Russian.

6. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021. 47 (11) . 1181–1247. doi:10.1007/s00134-021-06506-y

7. Vincent J.L., Opal S.M., Marshall J.C., Tracey K.J. Sepsis definitions: time for change. Lancet. 2013; 381 (9868): 774–775. doi:10.1016/S0140-6736(12)61815-7.

8. Torres A., Niederman M.S., Chastre J., et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J. 2017; 50 (3): 1700582. Published 2017 Sep 10. doi:10.1183/13993003.00582-2017.

9. Shankar-Hari M., Phillips GS, Levy M.L., et al. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315 (8): 775–787. doi:10.1001/jama.2016.0289.

10. Picchianti Diamanti A., Rosado M.M., Pioli C., Sesti G., Laganà B. Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity. International Journal of Molecular Sciences. 2020; 21 (9): 3330. https://doi.org/10.3390/ijms21093330.

11. Kullberg B.J., Arendrup M.C. Invasive Candidiasis. N Engl J Med. 2015; 373 (15) : 1445–1456. doi:10.1056/NEJMra1315399.

12. Mućka S., Jakubiak G.K., Pawlas N. Procalcitonin: Infection or Maybe Something More? Noninfectious Causes of Increased Serum Procalcitonin Concentration: Updated Knowledge. Life. 2025; 15 (3): 446. https://doi.org/10.3390/life15030446.

13. Ministry of Health of the Russian Federation. Clinical recommendations. Viral pneumonia. Approved in 2024. 80. In Russian.

14. Levy M., van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149:38-44. doi:10.1016/j.thromres.2016.11.007.

15. Schouten M., Virsinga W. J., Levy M., van der Poll T. Inflammation, endothelium and coagulation in sepsis. Leukocyte biology. 2008; 83 (3):536–545. doi:10.1189/jlb.0607373.

16. Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence. 2014; 5 (1): 66–72. doi:10.4161/viru.26907.

17. Angus D.C., van der Poll T. Severe sepsis and septic shock [published correction appears in N Engl J Med. 2013 Nov 21; 369 (21): 2069]. N Engl J Med. 2013; 369 (9): 840–851. doi:10.1056/NEJMra1208623.

18. Vincent J.L., Sakr Y., Sprung C.L., et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006; 34 (2): 344–353. doi:10.1097/01.ccm.0000194725.48928.3a.

19. Metlay J.P., Waterer G.W., Long A.C., et al. Diagnosis and Treatment of Adults with Communityacquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019; 200 (7): e45–e67. doi:10.1164/rccm.201908-1581ST.

20. Kalil A.C., Metersky M.L., Klompas M., et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63 (5): e61–e111. doi:10.1093/cid/ciw353.

21. Rhodes A., Evans L.E., Alhazzani W., et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017; 43 (3): 304–377. doi:10.1007/s00134-017-4683-6.

22. Seymour C.W., Liu V.X., Iwashyna T.J., et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315 (8): 762–774. doi:10.1001/jama.2016.0288.

23. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006; 34 (6): 1589–1596. doi:10.1097/01.CCM.0000217961.75225.E9.

24. Ferrer R., Martin-Loeches I., Phillips G., et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014; 42 (8): 1749–1755. doi:10.1097/CCM.0000000000000330.

25. Acute Respiratory Distress Syndrome Network, Brower R.G., Matthay M.A., et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000; 342 (18): 1301–1308. doi:10.1056/NEJM200005043421801.

26. Annane D., Renault A., Brun-Buisson C., et al. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med. 2018; 378 (9): 809–818. doi:10.1056/NEJMoa1705716.

27. De Backer D., Biston P., Devriendt J., et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010; 362 (9): 779–789. doi:10.1056/NEJMoa0907118.

28. Sklar M.C., Fan E., Goligher E.C. High-Frequency Oscillatory Ventilation in Adults With ARDS: Past, Present, and Future. Chest. 2017; 152 (6): 1306–1317. doi:10.1016/j.chest.2017.06.025.

29. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29 (7): 1303–1310. doi:10.1097/00003246-200107000-00002.

30. Walkey A.J., Wiener R.S. Macrolide antibiotics and survival in patients with acute lung injury. Chest. 2012; 141 (5): 1153–1159. doi:10.1378/chest.11-1908.

31. Kumar A., Zarychanski R., Light B., et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med. 2010; 38 (9): 1773–1785. doi:10.1097/CCM.0b013e3181eb3ccd.

32. Velissaris D., Zareifopoulos N., Karamouzos V., et al. Presepsin as a Diagnostic and Prognostic Biomarker in Sepsis. Cureus. 2021; 13 (5): e15019. Published 2021 May 13. doi:10.7759/cureus.15019.

33. Gibot S., Cravoisy A., Levy B., Bene M.C., Faure G., Bollaert P.E. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med. 2004; 350 (5): 451–458. doi:10.1056/NEJMoa031544.

34. Donadello K., Scolletta S., Covajes C., Vincent J.L. suPAR as a prognostic biomarker in sepsis. BMC Med. 2012; 10: 2. Published 2012 Jan 5. doi:10.1186/1741-7015-10-2.

35. Blauwkamp T.A., Thair S., Rosen M.J., et al. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease. Nat Microbiol. 2019; 4 (4): 663–674. doi:10.1038/s41564-018-0349-6.

36. Вирусные пневмонии: Учебное пособие для врачей / Е.В. Эсауленко, Ю.С. Александрович, А.Д. Бушманова и др. — СПб.: Изд-во СПбГПМУ, 2021. – 100 с.

37. Chaudhuri D., Nei A.M., Rochwerg B., et al. 2024 Focused Update: Guidelines on Use of Corticosteroids in Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia. Crit Care Med. 2024; 52 (5): e219–e233. doi:10.1097/CCM.0000000000006172.

38. Nair G.B., Niederman M.S. Updates on community acquired pneumonia management in the ICU. Pharmacol Ther. 2021;.217:.107663. doi:10.1016/j.pharmthera.2020.107663.

39. Cillóniz C., Torres A., Niederman M.S. Management of pneumonia in critically ill patients. BMJ. 2021; 375: e065871. Published 2021 Dec 6. doi:10.1136/bmj-2021-065871.

40. Lodise T.P., Kwa A., Cosler L., Gupta R., Smith R.P. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2007; 51 (11): 3977–3982. doi:10.1128/AAC.00006-07.

41. Martin-Loeches I., Lisboa T., Rodriguez A. et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 36, 612–620 (2010). https://doi.org/10.1007/s00134-009-1730-y.

42. Sligl W.I., Asadi L., Eurich D.T., Tjosvold L., Marrie T.J., Majumdar S.R. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med. 2014; 42 (2): 420–432. doi:10.1097/CCM.0b013e3182a66b9b.

43. Ito A., Ishida T., Tachibana H., Tokumasu H., Yamazaki A., Washio Y. Azithromycin combination therapy for community-acquired pneumonia: propensity score analysis. Sci Rep. 2019; 9 (1): 18406. Published 2019 Dec 5. doi:10.1038/s41598-019-54922-4.

44. Anderson R., Steel H.C., Cockeran R., et al. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro. J Antimicrob Chemother. 2007; 60 (5): 1155–1158. doi:10.1093/jac/dkm338.

45. Waterer G.W. Monotherapy versus combination antimicrobial therapy for pneumococcal pneumonia. Curr Opin Infect Dis. 2005; 18 (2): 157–163. doi:10.1097/01.qco.0000160906.02308.3c.

46. Baddour L.M., Yu V.L., Klugman K.P., et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004; 170 (4): 440–444. doi:10.1164/rccm.200311-1578OC.

47. Woolever N.L., Schomberg R.J., Cai S., Dierkhising R.A., Dababneh A.S., Kujak R.C. Pharmacist-Driven MRSA Nasal PCR Screening and the Duration of Empirical Vancomycin Therapy for Suspected MRSA Respiratory Tract Infections. Mayo Clin Proc Innov Qual Outcomes. 2020; 4 (5): 550–556. Published 2020 Aug 15. doi:10.1016/j.mayocpiqo.2020.05.002.

48. Rey S., Kulabukhov V.M., Popov A., et al. Hemoperfusion using the LPS-selective mesoporous polymeric adsorbent in septic shock: a multicenter randomized clinical trial. Shock. 2023; 59 (6): 846–854. doi:10.1097/SHK.0000000000002121.

49. Mitzner S., Kogelmann K., Ince C., Molnár Z., Ferrer R., Nierhaus A. Adjunctive Hemoadsorption Therapy with CytoSorb in Patients with Septic/Vasoplegic Shock: A Best Practice Consensus Statement. J Clin Med. 2023; 12 (23): 7199. Published 2023 Nov 21. doi:10.3390/jcm12237199.

50. Berlot G., Carocci P., Votrico V., et al. Real-World Outcomes of Hemoadsorption with CytoSorb® in Patients with Septic Shock: Insights from a Single-Center Study. J Intensive Care Med. Published online April 1, 2025. doi:10.1177/08850666251331905.